Evidence map›Paper›PMID 35978343›Full record

ArticleHarm reduction journal2022

Understanding heterogeneity among individuals who smoke cigarettes and vape: assessment of biomarkers of exposure and potential harm among subpopulations from the PATH Wave 1 Data.

Pavel N Lizhnyak, Brendan Noggle, Lai Wei, Jeffery Edmiston, Elizabeth Becker, Ryan A Black, Mohamadi Sarkar

Open access · goldAbstract read
In one paragraph

Article in Harm reduction journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Pavel N LizhnyakAltria Client Services LLC, 601 E. Jackson Street, Richmond, VA, 23219, USA.
Brendan NoggleAltria Client Services LLC, 601 E. Jackson Street, Richmond, VA, 23219, USA.
Lai WeiAltria Client Services LLC, 601 E. Jackson Street, Richmond, VA, 23219, USA.
Jeffery EdmistonAltria Client Services LLC, 601 E. Jackson Street, Richmond, VA, 23219, USA.
Elizabeth BeckerAltria Client Services LLC, 601 E. Jackson Street, Richmond, VA, 23219, USA.
Ryan A BlackAltria Client Services LLC, 601 E. Jackson Street, Richmond, VA, 23219, USA.
Mohamadi SarkarAltria Client Services LLC, 601 E. Jackson Street, Richmond, VA, 23219, USA. mohamadi.sarkar@altria.com.ORCID 0000-0002-1167-6140
Altria (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPeople who both smoke cigarettes and vape are often considered as a homogenous group even though multiple subgroups may exist. We examined biomarkers of exposure (BOE) and biomarkers of potential harm (BOPH) to differentiate between subgroups of people who smoke and vape based on PATH Study Wave 1 (2013-2014) data.

methodsWe compared people who only smoke cigarettes everyday (Group A, n = 2442) and people who only vape everyday (Group C, n = 169) against people who smoke and vape segmented into subgroups of people who frequently smoke and vape (Group B1, n = 169), frequently smoke and infrequently vape (Group B2, n = 678), frequently vape and infrequently smoke (Group B3, n = 57), and infrequently smoke and vape (Group B4, n = 66). Eighteen BOEs (representing exposure to TSNAs, nicotine, heavy metals, PAHs, and volatile organic compounds) and four BOPHs (representing inflammation and oxidative stress) were compared within the subgroups.

resultsLevels of many BOEs/BOPHs were higher among Group B2 relative to Groups B1, B3, and B4. Compared to Group A, many BOEs were significantly lower in Groups B3 (15/18) and B4 (17/18), and some BOEs were higher among B2 (4/18). Compared to Group C, significantly lower BOEs were observed for Group B4 (2/18).

conclusionsOverall, the levels of BOEs and BOPHs in people who smoke and vape are associated with frequency of cigarette smoking. Our findings indicate that not all people who smoke and vape are the same, and tobacco product use frequency should be considered when categorizing people who smoke and vape.

Indexed as

Cigarette SmokingElectronic Nicotine Delivery SystemsTobacco ProductsVapingBiomarkersHumansBiomarkersBiomarkers of exposureBiomarkers of potential harmCigarettesE-vapor/E-cigarettesPeople who smoke and vape

Identifiers

PMID35978343
PMCPMC9387076
OpenAlexW4292092988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.